FDA approves Gilead Science's hep B drug

The Food and Drug Administration recently approved Vemlidy, a once-daily treatment for patients with compensated liver disease caused by chronic hepatitis B virus.

According to Foster City, Calif.-based Gilead, Vemlidy is the first drug approved to treat this disease in almost a decade.

Vemlidy demonstrates similar antiviral efficacy at a dose one-tenth the size of Gilead's other hepatitis B drug Viread, which gained FDA approval in 2001.

More articles on supply chain:

Trucking industry hopeful Trump will loosen regulations, increase road spending
Leverage data analytics to control cath lab costs
FDA updates citizen petition regulations to prevent delays in drug approvals

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars